Synairgen PLC's (LON:SNG) Richard Marsden joins Proactive London's Katie Pilbeam to discuss three news updates so far this year.
Begining with the first patient dosed with its inhaled formulation of interferon beta-1a as part of its global phase III trial in people hospitalised coronavirus (COVID-19).
Secondly, they have put their last patient into their home trial, which means patients don't have to leave their homes at all, ideal for the current lockdown circumstances, all visits are conducted on a zoom call.
And finally, it's inhaled interferon beta-1a respiratory treatment has been included in a US government-sponsored coronavirus (COVID-19) clinical trial.